Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

26.85USD
18 Apr 2019
Change (% chg)

$0.12 (+0.45%)
Prev Close
$26.73
Open
$26.83
Day's High
$27.18
Day's Low
$26.57
Volume
3,676,284
Avg. Vol
5,268,861
52-wk High
$42.50
52-wk Low
$26.00

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 31.22 29.30 32.55
EPS (TTM): 1.23 -- --
ROI: 2.39 14.23 13.83
ROE: 5.71 15.46 15.25

U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

WASHINGTON The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe.

Apr 15 2019

UPDATE 1-U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

WASHINGTON, April 15 The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe.

Apr 15 2019

US STOCKS-Wall St set for muted open due to lack of fresh catalysts

* Futures dip: Dow 0.16 pct, S&P 0.12 pct, Nasdaq 0.09 pct (Changes comment, adds details, updates prices)

Mar 06 2019

Mylan shares sink as bleak profit outlook sparks growth concerns

Mylan NV shares slid 10 percent on Wednesday after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if its finances would worsen further.

Feb 27 2019

Mylan shares sink as bleak profit outlook sparks growth concerns

Feb 27 Mylan NV shares slid 10 percent on Wednesday after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if its finances would worsen further.

Feb 27 2019

Mylan quarterly profit, 2019 forecast miss Wall Street estimates

Generic drugmaker Mylan NV on Tuesday reported lower-than-expected fourth-quarter profit and forecast 2019 earnings well below Wall Street estimates, as it grapples with significant problems at its Morgantown, West Virginia, plant.

Feb 26 2019

UPDATE 2-Mylan quarterly profit, 2019 forecast miss Wall Street estimates

Feb 26 Generic drugmaker Mylan NV on Tuesday reported lower-than-expected fourth-quarter profit and forecast 2019 earnings well below Wall Street estimates, as it grapples with significant problems at its Morgantown, West Virginia, plant.

Feb 26 2019

Mylan's fourth-quarter revenue falls 5 percent

Feb 26 Drugmaker Mylan NV said fourth-quarter revenue fell 5 percent on Tuesday, due in part to costs related to issues and restructuring at its Morgantown, West Virginia, plant.

Feb 26 2019

Teva expects sales injection from U.S. EpiPen market

TEL AVIV Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020.

Feb 19 2019

UPDATE 2-Teva expects sales injection from U.S. EpiPen market

* Says will start supplying children's version within 3-4 months (Adds CEO comments, background, share price)

Feb 19 2019

Earnings vs. Estimates